Amicus Therapeutics ApS: Financial statements 2021
CVR: 39359340
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Amicus Therapeutics ApS (CVR 39359340) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK 644,168 and a net result of DKK 19,351 compared with DKK 21,886 the year before. That is an increase of 31.4% compared with the year before. Equity in the 2021 report amounted to DKK 249,060. The solvency ratio was 10.3%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 644,168
- Profit/Loss
- DKK 19,351
- Equity
- DKK 249,060
- Total Assets
- DKK 2,415,852
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | 644 t. | 19 t. | 249 t. | 1 |
| 2020 | - | 490 t. | 22 t. | 230 t. | 1 |
| 2019 | - | 2 mio. | 84 t. | 208 t. | 2 |
| 2018 | - | 2 mio. | 74 t. | 124 t. | 2 |
Official annual report
Find more companies like Amicus Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Amicus Therapeutics ApS has published its annual report for 2020. Gross profit came to DKK 490,223, and the net result was DKK 21,886.
As of May 3, 2021, Steven John Green has joined the board of directors of Amicus Therapeutics ApS.
As of May 3, 2021, Nicole Ruth Reichman has left the board of directors of Amicus Therapeutics ApS.
About Amicus Therapeutics ApS
Amicus Therapeutics ApS is a Danish company of the type Anpartsselskab based in København V, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Richard Gideon Morris. The board consists of Richard Gideon Morris (chair), Brian Keogh and Steven John Green. The company is owned by Amicus Therapeutics UK Ltd.. The company has 2 employees (2018). In 2025, the company reported a gross profit of DKK 1,441,140 and a net result of DKK 115,004 compared with DKK 16,475 the year before. Equity in the 2025 report amounted to DKK 424,641.